ORAGENICS


Associated tags: National Research Council, NIH, NRC, COVID-19, Bangladesh Technical Education Board, Infection, Research, Bacteria, Health, Pharmaceutical, Biotechnology, Infectious Diseases, NYSE, Oragene, Pharmaceutical industry

Locations: NEW YORK, FLORIDA, UNITED STATES, CANADA, GERMANY, II, TAMPA, FL, US, ER, FALLS, AUSTRALIA, NORTH AMERICA, NEW ZEALAND, IV, FANA, MA

Oragenics, Inc. Announces Private Placement

Retrieved on: 
Monday, August 7, 2023
Health, Infectious Diseases, COVID-19, Research, Science, Biotechnology, Common stock, Private, Act, Regulation D, Infection, NYSE, Common, Security (finance), Series

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the “Private Placement Offering”), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the “Common Stock”), and (ii) 404,728 shares of Series E Mirroring Preferred Stock (the “Series E Preferred Stock”).

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the “Private Placement Offering”), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the “Common Stock”), and (ii) 404,728 shares of Series E Mirroring Preferred Stock (the “Series E Preferred Stock”).
  • The Series E Preferred Stock has super voting rights on the proposed amendment equal to 2,500 votes per share of Series E Preferred Stock.
  • The Company intends to use the net proceeds from the offering for general corporate purposes.
  • The Common Stock and Series E Preferred Stock sold in the Private Placement Offering described above were issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, have not been registered under the Act, or applicable state securities laws.

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Retrieved on: 
Monday, June 5, 2023
COVID-19, Research, Infectious Diseases, Health Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Antigen, SARS-CoV-2, NRC, CHO, Infection, Transport, Immunization, NYSE, National Research Council, Vaccine, Oragene

The project, which aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1, is a collaboration with the National Research Council of Canada (NRC) and Inspirevax.

Key Points: 
  • The project, which aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1, is a collaboration with the National Research Council of Canada (NRC) and Inspirevax.
  • The grant awarded by CQDM is expected to help Oragenics fund the development of two to four well-characterized stable CHO pools expressing new, cross-protective vaccine antigens with well-established preclinical efficacy using intranasal immunization.
  • The grant funding is awarded through SynergiQC, a Quebec-based funding program for biopharmaceutical research created by CQDM.
  • CQDM extends its funding capacity to the development of biopharmaceutical products with high industrial and commercial value, such as more competitive molecules and other technologies.

Oragenics to Participate in the World Vaccine Congress Washington

Retrieved on: 
Wednesday, March 29, 2023
Health, Infectious Diseases, Genetics, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, GLP, Human, SARS-CoV-2, Toxicity, Infection, Immunoglobulin A, Antibody, Patient, Blood, Immunoglobulin G, Scientific Reports, Toxicology, Rabbit, Mouse, Viral load, NYSE, Safety, Pharmaceutical industry, Vaccine, Nature, Oragene, D.C

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C.
    Ms. Murphy will be holding meetings to highlight the company’s lead COVID-19 intranasal vaccine candidate, NT-CoV2-1, and to explore partnering opportunities.
  • Oragenics believes an intranasal COVID-19 vaccine holds several potential benefits compared with injectable vaccines, including targeting mucosal immunity, reducing transmission and offering a needle-free alternative for patients.
  • “I am excited to take part in the World Vaccine Congress this year and share our progress toward a highly differentiated intranasal COVID-19 vaccine,” said Ms. Murphy.
  • Earlier this month Oragenics entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301.

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Methicillin-resistant Staphylococcus aureus, NYSE, Infection, VRE, Daptomycin, Phenotype, Enterococcus-1 RNA motif, Methicillin, MRSA, Vancomycin, Oxacillin, Vaccine, Antibiotics, Oragene

Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.

Key Points: 
  • Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.
  • Oragenics’ lantibiotics platform is focused on the development of new antibiotics effective against certain pathogens including vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
  • Oragenics is focused on addressing this unmet medical need through its novel lantibiotics platform, and the results of its work with Linnaeus Bioscience advance Oragenics’ long-term mission to become a provider of effective treatments for infectious diseases.
  • Oragenics remains committed to fighting infectious diseases through the development of its lantibiotics pipeline against MRSA and VRE pathogens.

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Retrieved on: 
Wednesday, March 8, 2023
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, University, Pharmacy, NYSE, Rehabilitation, HEALTH, Assistant Secretary of the Treasury for Management, Infection, Nursing, CFO, BYU College of Family, Home and Social Sciences, Management, Oragene

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023.
  • Ms. Huffman is a seasoned financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies.
  • In 2019, Ms. Huffman was a founding member of Banyan Pediatric Care Centers and served as its Chief Financial Officer.
  • Prior to Arboreta Healthcare, Ms. Huffman was the Chief Financial Officer for Signature HomeNow, a home healthcare services company.

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

Retrieved on: 
Wednesday, March 1, 2023
Biotechnology, Pharmaceutical, Health, COVID-19, Safety, Good laboratory practice, Immunoglobulin G, NYSE, Immunoglobulin A, Patient, Trial of the century, JDC, Rabbit, Bangladesh Technical Education Board, Infection, Vaccine, Viral load, Pharmaceutical industry, Oragene

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.
  • Under the exclusive licensing agreement, Oragenics will pursue the development of NT-CoV2-1 with Inspirevax’s novel BDX301 intranasal mucosal adjuvant.
  • Additionally, the agreement provides a certain period of time for the companies to expand their collaboration to pursue the development of additional intranasal vaccine candidates using Inspirevax’s adjuvants.
  • We are excited to collaborate with the experts at Inspirevax to pursue the development of novel intranasal vaccine candidates,” explains Kimberly Murphy, President and Chief Executive Officer of Oragenics.

Oragenics, Inc. Regains Compliance with NYSE American

Retrieved on: 
Friday, February 3, 2023
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, NYSE American, NYSE, Infection, Pharmaceutical industry, Cryptocurrency

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has received formal notice from the NYSE American, LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing standards.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has received formal notice from the NYSE American, LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing standards.
  • The notice the Company received from NYSE American on February 1, 2023 indicated that the Company resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide.
  • The notice further stated that the below compliance (“.BS) indicator will no longer be disseminated and the Company has been removed from the NYSE American noncompliant issuers on the NYSE American’s website.

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

Retrieved on: 
Friday, December 23, 2022
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, Transfer, COVID-19, Risk, Reverse stock split, NYSE, Infection, NYSE American, Exercise, OTC Bulletin Board, Security (finance)

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors (the “Board”) on December 22, 2022 approved a 1-for-60 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the Company’s authorized shares of common stock (the “Reverse Stock Split”), such that, following the consummation of the Reverse Stock Split, the number of authorized shares of common stock will be reduced from 250,000,000 shares to 4,166,666 shares.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors (the “Board”) on December 22, 2022 approved a 1-for-60 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the Company’s authorized shares of common stock (the “Reverse Stock Split”), such that, following the consummation of the Reverse Stock Split, the number of authorized shares of common stock will be reduced from 250,000,000 shares to 4,166,666 shares.
  • As a result of the Reverse Stock Split, the Company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on January 23, 2023.
  • As a result of the Reverse Stock Split, every 60 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of holders, and the number of issued and outstanding common shares will be reduced from approximately 117.6 million shares to approximately 1.9 million shares.
  • The Reverse Stock Split will neither affect the par value of the common stock nor will it affect the Company’s authorized preferred stock, except to affect, where applicable, the conversion rates of outstanding shares of preferred stock.

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

Retrieved on: 
Thursday, December 22, 2022
Pharmaceutical, Health, COVID-19, Blood, Mouse, Immunoglobulin A, GLP, COVID-19, Toxicity, Viral load, Scientific Reports, NYSE, Infection, Severe acute respiratory syndrome coronavirus 2, Safety, Rabbit, Antibody, Human, Immunoglobulin G, Good laboratory practice, Pharmaceutical industry, Vaccine, Oragene, Nature

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate.
  • “There is an unmet medical need for an intranasally administered COVID-19 vaccine.
  • We are encouraged by these favorable toxicology study results, which advance the preclinical work required for pursuing regulatory permission to begin human testing.
  • This marks an important milestone in the progress of bringing an intranasal COVID-19 vaccine to the market,” said Kim Murphy, President and Chief Executive Officer of Oragenics.

Oragenics, Inc. Receives NYSE American Notice

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, Bangladesh Securities and Exchange Commission, COVID-19, Security (finance), NYSE, Infection, NYSE American, Notice, Audit

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that it received a Notice (the “Notice”) on December 19, 2022 from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that it received a Notice (the “Notice”) on December 19, 2022 from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").
  • The Notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on the NYSE American under the symbol “OGEN” but will have an added designation of “BC” to indicate that the Company is not in compliance with the NYSE American’s listing standards.
  • Additionally, the Notice does not result in the immediate delisting of the Company’s stock from the NYSE American.
  • The Company is actively engaged in discussions with the NYSE American and is developing plans to regain compliance with the NYSE American’s continued listing standards within the time period indicated.